The above studies have provided an intriguing insight into a novel approach for treatment of C9orf72 ALS/FTD through suppression of specific transcriptional regulators (i.e., PAF1C, Supt4h1 or Supt5h). This evidence concerns the gene SUPT5H and frontotemporal dementia.